Clarametyx Biosciences

Serious bacterial infections, which are largely biofilm-driven, are driving the global threat of antimicrobial resistance. More antibiotics alone will not solve the problem.

‍

Conventional antibiotics and innate immune effectors cannot effectively kill biofilm-residing bacteria. Biofilm-driven need for higher doses and repeated, prolonged use of antibiotics contributes to resistance. Recent WHO, Lancet and BIO reports cite major failures in antibiotic development and innovation.

Clarametyx's approach: Target the universal biofilm structure itself with therapeutics and vaccines to eliminate this defense mechanism and increase effectiveness of immune intervention and antibiotics to clear infections.

‍

     1. Enables Rapid Immune Intervention.

     2. Dramatically Improves Susceptibility to Antibiotics.

     3. Reduces Site-Specific Inflammation to Improve Recovery.

     1. Novel immune-enabling, pro-stewardship technology platform appliable to all bacterial biofilm-associated diseases.

     2. Premise derived from groundbreaking discoveries in biofilm structure.

     3. CMTX-101 therapeutic for pneumonia and cystic fibrosis complements front line antibiotics for superiority to SoC.

     4. CMTX-301 broad-spectrum vaccine for otitis media addresse.